Literature DB >> 18714036

Nucleotide oligomerization domains 1 and 2: regulation of expression and function in preadipocytes.

Thorsten Stroh1, Arvind Batra, Rainer Glauben, Inka Fedke, Ulrike Erben, Anjo Kroesen, Markus M Heimesaat, Stefan Bereswill, Stephen Girardin, Martin Zeitz, Britta Siegmund.   

Abstract

Translocation of bacteria into the mesenteric fat during intestinal inflammation and the expression of functional TLR1-9 in murine preadipocytes and adipocytes suggest an active role for these cells in innate immunity. The present study focuses on nucleotide oligomerization domains 1 and 2 representing intracellular pattern recognition receptors that sense motifs derived from bacterial peptidoglycans. On mRNA level nucleotide oligomerization domain 1 was found to be constitutively expressed in the preadipocyte cell line 3T3L1 and in primary preadipocytes isolated from murine mesenteric fat, while nucleotide oligomerization domain 2 was only weakly expressed by these cells. Treatment with lactyl-tetra-diaminopimelic acid, muramyl dipeptide, LPS, IL-1beta, and TNF-alpha did not affect cellular nucleotide oligomerization domain 1 mRNA amounts. Except muramyl dipeptide, all factors significantly increased nucleotide oligomerization domain 2 mRNA in mesenteric fat preadipocytes after 4 h. However, specific stimulation of nucleotide oligomerization domain 1 induced IL-6 synthesis in preadipocytes from wild-type or TLR2/4-deficient mice. Confirming nucleotide oligomerization domain 1 specificity, transfection of nucleotide oligomerization domain 1-specific small interfering RNA significantly blocked the effect of lactyl-tetra-diaminopimelic acid on IL-6 production. With specific inhibitors and a NF-kappaB reporter plasmid, nucleotide oligomerization domain 1-mediated activation of NF-kappaB was shown to be responsible for the induction of IL-6 in preadipocytes. In addition, expression of functional nucleotide oligomerization domain 1 could be confirmed in primary human preadipocytes. In summary, we here identified preadipocytes as a novel cell population expressing nucleotide oligomerization domains 1 and 2. Not regulated on transcriptional level, nucleotide oligomerization domain 1 in preadipocytes serves as a sensor for bacterial degradation products and triggers proinflammatory effector responses. Thus, our results further strengthen the allocation of the mesenteric fat and especially of preadipocytes to the innate immune system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18714036     DOI: 10.4049/jimmunol.181.5.3620

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Adipose tissue and inflammatory bowel disease pathogenesis.

Authors:  Christopher Fink; Iordanes Karagiannides; Kyriaki Bakirtzi; Charalabos Pothoulakis
Journal:  Inflamm Bowel Dis       Date:  2012-03-08       Impact factor: 5.325

2.  Convergence of innate immunity and insulin resistance as evidenced by increased nucleotide oligomerization domain (NOD) expression and signaling in monocytes from patients with type 2 diabetes.

Authors:  Abhijit Shiny; Bhaskaran Regin; Venketesan Balachandar; Kuppan Gokulakrishnan; Viswanathan Mohan; Subash Babu; Muthuswamy Balasubramanyam
Journal:  Cytokine       Date:  2013-09-06       Impact factor: 3.861

Review 3.  Extraluminal factors contributing to inflammatory bowel disease.

Authors:  Arvind Batra; Thorsten Stroh; Britta Siegmund
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

4.  Relevance of the myeloid differentiation factor 88 (MyD88) on RANKL, OPG, and nod expressions induced by TLR and IL-1R signaling in bone marrow stromal cells.

Authors:  Fábio Renato Manzolli Leite; Sabrina Garcia de Aquino; Morgana Rodrigues Guimarães; Joni Augusto Cirelli; Dario S Zamboni; João S Silva; Carlos Rossa Junior
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 5.  Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.

Authors:  Siddharth Singh; Parambir S Dulai; Amir Zarrinpar; Sonia Ramamoorthy; William J Sandborn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-30       Impact factor: 46.802

Review 6.  Periodontal innate immune mechanisms relevant to atherosclerosis.

Authors:  S Amar; M Engelke
Journal:  Mol Oral Microbiol       Date:  2014-12-29       Impact factor: 3.563

7.  Nucleotide-binding oligomerization domain protein 2 deficiency enhances neointimal formation in response to vascular injury.

Authors:  Min-Young Kwon; Xiaoli Liu; Seon-Jin Lee; Young-Ho Kang; Augustine M K Choi; Ki-Up Lee; Mark A Perrella; Su Wol Chung
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

8.  Pivotal role of NOD2 in inflammatory processes affecting atherosclerosis and periodontal bone loss.

Authors:  Huaiping Yuan; Sami Zelkha; Sami Zelka; Marina Burkatovskaya; Rohit Gupte; Susan E Leeman; Salomon Amar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

9.  Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients.

Authors:  Martin H Holtmann; Frank Krummenauer; Christina Claas; Kristina Kremeyer; Dirk Lorenz; Olivia Rainer; Iris Vogel; Ulrich Böcker; Stephan Böhm; Carsten Büning; Rainer Duchmann; Guido Gerken; Hans Herfarth; Norbert Lügering; Wolfgang Kruis; Max Reinshagen; Jan Schmidt; Andreas Stallmach; Jürgen Stein; Andreas Sturm; Peter R Galle; Daan W Hommes; Geert D'Haens; Paul Rutgeerts; Markus F Neurath
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

10.  Insulin resistance corresponds with a progressive increase in NOD1 in high fat diet-fed mice.

Authors:  Aditya Sharma; Sushmita Singh; Alok Mishra; Amit K Rai; Ishbal Ahmad; Shadab Ahmad; Farah Gulzar; Jonathan D Schertzer; Ashutosh Shrivastava; Akhilesh K Tamrakar
Journal:  Endocrine       Date:  2022-02-02       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.